• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服抗真菌药物治疗甲真菌病后真菌学治愈的预后因素。

Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents.

作者信息

Sigurgeirsson B, Paul C, Curran D, Evans E G V

机构信息

Department of Dermatology, University of Iceland and Landspitalinn, University Hospital, Reykjavik, Iceland.

出版信息

Br J Dermatol. 2002 Dec;147(6):1241-3. doi: 10.1046/j.1365-2133.2002.05035.x.

DOI:10.1046/j.1365-2133.2002.05035.x
PMID:12452877
Abstract

BACKGROUND

There is considerable literature on the efficacy and safety of various drugs used in treating onychomycosis; however, little information is available regarding prognostic factors which may be associated with non-response to conventional treatment.

OBJECTIVES

To identify parameters influencing mycological cure at 72 weeks following treatment of toenail onychomycosis with oral antifungal agents.

METHODS

Univariate and multivariate logistic regression analysis from a randomized double-blind controlled trial including 496 patients with toenail onychomycosis caused by dermatophytes.

RESULTS

Baseline parameters including patient's age, gender, weight, number of toenails involved, percentage of nail involvement, duration of infection, history of previous treatment were not associated with mycological cure. In the multivariate prognostic factor analysis based on factors assessed at week 12, positive mycological culture at 12 weeks [odds ratio (OR): 0.583; 95% confidence interval (CI): 0.370-0.918] was negatively associated with mycological cure at 72 weeks. Similarly, in the multivariate prognostic factor analysis based on factors assessed at week 24, positive direct microscopy at 24 weeks (OR: 0.373; 95% CI: 0.211-0.659) and mycological culture at 24 weeks (OR: 0.293; 95% CI: 0.168-0.513) were negatively associated with mycological cure at 72 weeks.

CONCLUSIONS

Mycological culture at 12 and 24 weeks and direct microscopic examination at 24 weeks can help in early identification of patients failing to respond to conventional oral antifungal treatment.

摘要

背景

关于用于治疗甲癣的各种药物的疗效和安全性,已有大量文献报道;然而,关于可能与对传统治疗无反应相关的预后因素的信息却很少。

目的

确定口服抗真菌药物治疗趾甲甲癣72周后影响真菌学治愈的参数。

方法

对一项随机双盲对照试验进行单因素和多因素逻辑回归分析,该试验纳入了496例由皮肤癣菌引起的趾甲甲癣患者。

结果

包括患者年龄、性别、体重、受累趾甲数量、甲受累百分比、感染持续时间、既往治疗史等基线参数与真菌学治愈无关。在基于第12周评估因素的多因素预后因素分析中,第12周真菌培养阳性[比值比(OR):0.583;95%置信区间(CI):0.370 - 0.918]与72周时的真菌学治愈呈负相关。同样,在基于第24周评估因素的多因素预后因素分析中,第24周直接镜检阳性(OR:0.373;95% CI:0.211 - 0.659)和第24周真菌培养阳性(OR:0.293;95% CI:0.168 - 0.513)与72周时的真菌学治愈呈负相关。

结论

第12周和第24周的真菌培养以及第24周的直接镜检有助于早期识别对传统口服抗真菌治疗无反应的患者。

相似文献

1
Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents.口服抗真菌药物治疗甲真菌病后真菌学治愈的预后因素。
Br J Dermatol. 2002 Dec;147(6):1241-3. doi: 10.1046/j.1365-2133.2002.05035.x.
2
Prognostic factors for cure following treatment of onychomycosis.治疗甲真菌病后治愈的预后因素。
J Eur Acad Dermatol Venereol. 2010 Jun;24(6):679-84. doi: 10.1111/j.1468-3083.2009.03487.x. Epub 2009 Nov 19.
3
Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study.特比萘芬与伊曲康唑治疗甲真菌病的长期疗效:一项为期5年的双盲前瞻性随访研究。
Arch Dermatol. 2002 Mar;138(3):353-7. doi: 10.1001/archderm.138.3.353.
4
Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus.脉冲式伊曲康唑与连续服用特比萘芬治疗糖尿病患者皮肤癣菌性 toenail 甲真菌病的疗效比较 。 注:原文中“toenail”可能表述有误,结合语境推测可能是“toenail onychomycosis”,意为“趾甲甲真菌病” ,翻译时按此理解进行了调整,使译文更符合医学逻辑。
J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1188-93. doi: 10.1111/j.1468-3083.2006.01698.x.
5
Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?疾病严重程度是甲癣治疗后治愈的预后因素吗?
J Drugs Dermatol. 2018 Feb 1;17(2):175-178.
6
Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain.阿莫罗芬与伊曲康唑联合治疗重度趾甲甲真菌病:西班牙一项开放性随机试验的结果
Br J Dermatol. 2001 Oct;145 Suppl 60:21-6.
7
Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.脉冲式与连续服用特比萘芬治疗甲癣的随机双盲对照试验
J Am Acad Dermatol. 2005 Oct;53(4):578-84. doi: 10.1016/j.jaad.2005.04.055.
8
Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group.连续服用特比萘芬与间歇服用伊曲康唑治疗 toenail 甲真菌病的双盲随机研究。LION 研究组。 (注:这里“toenail”在医学语境下可能是“趾甲”的意思,但从字面看不太准确,可能原文表述有误,正常应该是“onychomycosis of toenails”之类更准确表述趾甲甲真菌病的形式 )
BMJ. 1999 Apr 17;318(7190):1031-5. doi: 10.1136/bmj.318.7190.1031.
9
Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.特比萘芬与伊曲康唑治疗趾甲癣感染的随机双盲对照研究。第七届兰美抒德国甲真菌病研究组
BMJ. 1995 Oct 7;311(7010):919-22. doi: 10.1136/bmj.311.7010.919.
10
Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group.在一项比较6周和12周治疗的双盲试验中,对特比萘芬治疗甲癣6周的疗效进行评估。拉各斯V研究组。
Br J Dermatol. 1997 May;136(5):737-42.

引用本文的文献

1
On the Basis of Sex: Impact and Treatment of Toenail Onychomycosis in Female Patients.基于性别:女性患者趾甲甲真菌病的影响与治疗
J Clin Aesthet Dermatol. 2023 Oct;16(10):52-57.
2
Updated Perspectives on the Diagnosis and Management of Onychomycosis.甲癣诊断与治疗的最新观点
Clin Cosmet Investig Dermatol. 2022 Sep 15;15:1933-1957. doi: 10.2147/CCID.S362635. eCollection 2022.
3
Update on therapy for superficial mycoses: review article part I.浅表真菌病治疗进展:综述文章第一部分
An Bras Dermatol. 2013 Sep-Oct;88(5):764-74. doi: 10.1590/abd1806-4841.20131996.
4
Update on terbinafine with a focus on dermatophytoses.特比萘芬更新:重点关注皮肤癣菌病。
Clin Cosmet Investig Dermatol. 2009 Apr 21;2:49-63. doi: 10.2147/ccid.s3690.